A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma | Zendy

Haiying Wang | Zendy; Zhihua Yao | Zendy; Hong Tang | Zendy; Yan Zhao | Zendy; Shuiling Jin | Zendy; Wenping Zhou | Zendy; Shuna Yao | Zendy; Shujun Yang | Zendy; Yanyan Liu | Zendy; Suxia Luo | Zendy

Open Access

A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma

Author(s) -

Haiying Wang,

Zhihua Yao,

Hong Tang,

Yan Zhao,

Shuiling Jin,

Wenping Zhou,

Shuna Yao,

Shujun Yang,

Yanyan Liu,

Suxia Luo

Publication year - 2016

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.13602

Subject(s) - medicine , paclitaxel , neutropenia , leukopenia , cisplatin , regimen , oncology , gastroenterology , progression free survival , chemotherapy , adverse effect

In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable. The current clinical study was conducted to retrospectively compare the efficacy and safety of first-line paclitaxel/S-1(PS) and paclitaxel/cisplatin(TP) regimens in advanced ESCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research